In 1984, a man named Al Czap started a supplement company in South Carolina with a strange business plan: don't sell to consumers.
Sell to doctors instead. Make the products clean enough that a practitioner would put their own name behind them. Then wait.
That is not a growth strategy. That is a forty-year bet that the slowest possible path to credibility is the only real one.
On Tuesday, Procter and Gamble agreed to buy that company, Thorne, for $3.8 billion.
Before I go further: I run a supplement company. Bluegrass Precision Supplements competes, in a very small way, in the same category Thorne dominates. So I am not a neutral observer and I am not going to pretend to be. Discount accordingly.
I still think this is the most interesting business story of the week, and most of the coverage is looking at the wrong number.
The numbers everyone is looking at
Thorne went public in late 2021 at roughly a $525 million valuation. L Catterton took it private in 2023 for $680 million. P&G is now paying $3.8 billion.
That is more than five and a half times in under three years. Revenue is reportedly headed toward $650 million this year. Most of it comes from buyers under 40, with direct-to-consumer sales surging.
Every trade publication ran the same framing: big consumer goods company buys into the wellness boom. Which is true, and part of a pattern, since Unilever picked up the gummy brand Grüns earlier this year and P&G's health division already owns Metamucil, Align, and New Chapter.
But that framing treats this as a category bet, and I do not think it is. If P&G wanted supplement revenue, they already had a supplement business, a manufacturing arm, and enough marketing budget to buy attention in any aisle they choose. They did not need $3.8 billion to sell capsules.
They needed it to buy the forty years.
Why the forty years cost that much
Here is what people outside medicine do not fully appreciate about this category.
Supplements are not approved before they reach the shelf. There is no premarket review confirming the bottle contains what the label says, at the dose it claims, without something extra in it. The verification burden sits entirely with the buyer, and most buyers have no way to carry it.
Which makes the product close to a commodity. The magnesium in a rigorous bottle and the magnesium in a careless one often came from the same short list of global suppliers. What separates them is process: third-party testing, batch documentation, someone competent standing between the raw material and the label.
Thorne runs its own manufacturing facility rather than farming it out. They built their position through the practitioner channel and NSF Certified for Sport credibility. Their own numbers cite tens of thousands of healthcare professionals, thousands of athletes, and more than a hundred professional sports teams.
That is the asset. Not the pills. The fact that a physician will write the brand name on a piece of paper and hand it to a patient who is going to swallow it.
You cannot buy that. You cannot accelerate it with capital, which is the whole reason it costs $3.8 billion instead of the roughly $650 million of revenue it produces. Every other input in this business can be purchased on a timeline. That one can only be waited out.
What happens next is the part I keep turning over
Trust in this category gets built partly through restraint. Thorne's credibility came in part from where it was not, from being harder to get than the alternative, which functioned as a signal all by itself.
The entire point of an acquisition at this scale is distribution. That is the synergy. That is the investment thesis. P&G is exceptionally good at putting things in front of everyone, in roughly seventy countries.
But scale applies pressure to the exact property that justified the price. This is the oldest pattern in consumer goods and we know its shape. The specialty brand is acquired, distribution expands, margin pressure arrives on schedule, and eighteen months later someone proposes a cost-optimized formulation that is technically the same product.
Nobody in that meeting is a villain. Every individual decision is defensible on its own. The brand erodes anyway, because the thing being protected was never written down as an asset with someone accountable for it.
There is a real case on the other side and I am not going to skip it. P&G has capital Thorne never had, and capital in this category could fund actual clinical trials instead of marketing that sounds like clinical trials. Their quality control at scale is better than most of this industry. Prices may come down. If more people end up with a verified product instead of whatever is cheapest at the pharmacy, that is a public health win and I will not sneer at it.
What I would watch
Nothing changes on the shelf this month. The deal is not expected to close until the second quarter of P&G's fiscal 2027, pending regulatory approval.
Over the next eighteen months, three things will tell you which way it went:
Do the certifications hold. NSF Certified for Sport is verifiable and expensive to maintain. If it quietly disappears from a product line, that is your signal.
Does the practitioner channel stay a channel or become a story. There is a meaningful difference between selling to clinicians and featuring clinicians in the advertising.
Read the label again in a year. Not the front. The other ingredients line, and the actual doses. Formulation drift is the least visible way a brand gets cheaper.
The bottom line
I do not know which way this goes, and anyone telling you confidently is selling something.
What I keep coming back to is the shape of the story. A guy starts a company in 1984 and chooses the slow path on purpose. He sells to the hardest customers in the market, the ones who lose something real if the product is wrong. He does that for four decades while faster companies come and go around him.
And the reward for getting it right is an offer to hand it to someone with the distribution to make the carefulness harder to maintain.
That is not a tragedy. It might be the best possible outcome for everyone involved, and I am not sure I would have said no. I am not sure anyone would.
But it is worth sitting with on a Saturday, especially if you are building something small right now and wondering whether the slow way is worth it.
It is. That is what the price tag says. You spend forty years earning the right to be trusted, and it turns out that is the only thing in the whole business that money cannot manufacture.
Just know what you are being offered when someone finally tries to buy it.
Reply and tell me.
That's all for this week.
See you next Saturday.